Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill could reduce Blood-Letting for rare blood cancer patients

NCT ID NCT05558696

Disease control Sponsor: Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 study tested an oral drug called bomedemstat in 20 adults with polycythemia vera, a rare blood cancer that causes too many red blood cells. The main goal was to see if the drug could safely lower red blood cell levels enough to avoid routine blood removal (phlebotomy) for at least 12 weeks. Participants who benefited could continue treatment for up to a year. The study is complete, and results will show whether bomedemstat is a promising new option for controlling this condition.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
bomedemstat (oral capsule)
What this could lead to
If successful, bomedemstat could offer a new oral treatment option to control red blood cell levels in people with polycythemia vera, reducing the need for blood removal procedures.
What could go wrong
This is a small, early-phase study (20 participants) focused on safety and short-term effects. The drug may not work in larger groups or could cause side effects. Long-term benefits are not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

20 people

The number who actually took part.

Started

Sep 2023

Finished

Jul 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Has a diagnosis of Polycythemia Vera per World Health Organization (WHO) diagnostic criteria for myeloproliferative neoplasms * Has a bone marrow fibrosis score of Grade 0 or Grade 1 * Has failed at least one standard cytoreductive therapy to lower hematocrit * Has a life expectancy \>36 weeks * Has discontinued prior cytoreductive therapy for 2 weeks (4 weeks for interferon) prior to study drug initiation Exclusion Criteria: * Has an Eastern Cooperative Oncology Group (ECOG) performance status of 3 or greater * Has unresolved treatment related toxicities from prior therapies (unless resolved to ≤ Grade 1) * Has an uncontrolled active infection * Has a known human immunodeficiency virus (HIV) infection or active Hepatitis A, Hepatitis B or Hepatitis C virus infection * Has evidence of increased risk of bleeding, including known bleeding disorders * Is pregnant or lactating

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Polycythemia vera are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acquired polycythemia vera

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Polycythemia vera

Contacts and locations

Locations

  • BRCR Global ( Site 0120)

    Plantation, Florida, 33322, United States

  • Boston Pilgrim Hospital ( Site 0207)

    Boston, Lincolnshire, PE21 9QS, United Kingdom

  • Comprehensive Cancer Centers of Nevada - Peak ( Site 0118)

    Las Vegas, Nevada, 89128, United States

  • Duke University Medical Center ( Site 0016)

    Durham, North Carolina, 27705, United States

  • Gloucestershire Royal Hospital ( Site 0205)

    Gloucester, England, GL1 3NN, United Kingdom

  • Guys and St Thomas NHS Foundation Trust - Guys Hospital ( Site 0020)

    London, London, City of, SE1 9RT, United Kingdom

  • Hematology Oncology of the North Shore ( Site 0104)

    Skokie, Illinois, 60076-1264, United States

  • Huntsman Cancer Hospital at the University of Utah ( Site 0119)

    Salt Lake City, Utah, 84112, United States

  • Imperial College London ( Site 0025)

    London, Great Britain, W12 0HS, United Kingdom

  • Monash Medical Centre ( Site 0006)

    Clayton, Victoria, 3168, Australia

  • OHSU Knight Cardiovascular Institute Cardiology Clinic - South Waterfront ( Site 0102)

    Portland, Oregon, 97239-4503, United States

  • Ohio State University Comprehensive Cancer Center ( Site 0103)

    Columbus, Ohio, 43203, United States

  • Royal Gwent Hospital ( Site 0201)

    Newport, Wales, NP9 2UB, United Kingdom

  • Royal Perth Hospital ( Site 0504)

    Perth, Western Australia, 6000, Australia

  • Sunshine Coast Hematology and Oncology Clinic (Site 0506)

    Sunshine Coast, Queensland, 4556, Australia

  • United Lincolnshire Hospitals NHS Trust ( Site 0204)

    Lincoln, Great Britain, LN2 5QY, United Kingdom

  • University of Michigan Comprehensive Cancer Center ( Site 0008)

    Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.